Internet Explorer does not cooperate with this site. Please see below for options that work with APNA eLearning. *

304-23: Is This What They Mean by a Paradigm Shift? Understanding New Perspectives and Treatments in Depression

Get updates on the new medications approved for major depressive disorder (MDD) and how these new medications represent a shift in the understanding of the neurobiology of depression and mood disorders.

Presenter:  Capt. Joseph Holshoe, PMHNP-BC

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose.  Off-label uses will be discussed during this presentation.

Session Length:  1 hour 30 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Conceptualize new treatments in depression in the paradigm of neuronal pathway hypothesis.

Keywords:  Depression, Neurotransmitters, Treatment Resistant Depression, TRD, ECT, TMS

Nursing Continuing Professional Development:
1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Access to this course will end: July 31, 2025

*For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.